中國飛鶴(06186.HK)擬回購不超2億美元股份
格隆匯6月9日丨中國飛鶴(06186.HK)宣佈其擬動用購回授權,自2021年6月9日起直至公司下屆股東周年大會結束止(即購回授權屆滿時)於公開市場購回公司股份。股份購回計劃擬動用不超過2億美元資金用於購回股份。公司將從現有可動用現金儲備及自由現金流量為購回撥付資金。
公司管理團隊對公司實現此前披露的2023年中期經營目標和2028年長期經營目標充滿強烈信心。股份購回計劃反映在公司市場領導地位的驅動下,董事會及管理團隊對公司目前及長期的業務展望以及增長充滿信心。董事會認為,股份購回計劃符合公司及其股東的整體最佳利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.